GBS Inc. - Real-time, point-of-care testing at the tip of your tongue

Our Mission

GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care.

With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.

Latest News

GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test

New York, New York July 26, 2021 GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today […]

With our world-first Biosensor Platform technology, GBS Inc. will develop and launch two urgently needed non-invasive, real-time diagnostic tests.

OUR PLATFORM

The Saliva Glucose Biosensor

Replacing painful finger-prick blood glucose testing for people living with diabetes.

Learn More

SARS-COV-2 Antibody Biosensor

A non-invasive, real-time antibody test to monitor infection and immunity levels in the fight against COVID-19.

Learn More

Behind the Technology

Meet the team at the Centre for Organic Electronics behind the biosensor technology.

A Member of The iQ Group Global

GBS Inc. is a member of The iQ Group Global, an award-winning consortium of companies that finds, funds and develops innovative bioscience intellectual property from world-class academic institutions to create life-changing medical innovations.